PPARG and metabolic dysfunction-associated steatohepatitis: While there was no improvement of NASH fibrosis in the FLIRT study [68], hepatic fibrosis was, nonetheless, improved by rosiglitazone in MCD diet-fed C57BL6/J mice, and this was attributed to activation of PPARγ, which caused reduced HSC activation and suppressed expression of TGF-β1 and CCN2 [52].